Recombinant Anti-CD3 x Anti-CD38 Bispecific Antibody (Bi-nanobody) is designed to be expressed as a VHH from anti-CD3 antibody variable domains fused with a VHH from an anti-CD38 antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can block two receptors simultaneously. It is designed for the research of Multiple myeloma (MM) therapy.